Scholarlink

<p>Epidemiologic evidence links follicle–stimulating hormone (FSH), a pituitary glycoprotein that rises during menopause, to memory loss, fat accumulation, and bone loss. We and others have shown that the attenuation of FSH signaling, either genetically or pharmacologically, prevents memory loss, fat accrual, and bone loss in multiple mouse models. Here, we investigated whether the genetic depletion of the FSH receptor (<i>Fshr</i>) affects recognition memory, body composition, and bone mineral density (BMD) in two AD mouse models. We generated male and female <i>3xTg</i> and <i>APP</i>-KI mice carrying the <i>Fshr</i><sup>+/+</sup>, <i>Fshr</i><sup>+/−</sup>, and <i>Fshr</i><sup>−/−</sup> genotypes. Recognition memory was evaluated using the Novel Object Recognition (NOR) test. Body composition (fat, lean, and total mass) and site–specific bone mineral density (femur, tibia, L3–L5 spine) measurements were made using quantitative nuclear magnetic resonance (qNMR) and dual-energy X-ray absorptiometry (DXA), respectively, at two time points. Given that female <i>Fshr</i><sup>−/−</sup> genotypes are otherwise hypogonadal, they were implanted with 17β–estradiol pellets at 8–12 weeks of age to normalize serum estrogen. At the early time point, the deficit in recognition memory was rescued in female <i>3xTg</i>;<i>Fshr</i><sup>−/−</sup> and <i>APP</i>-KI;<i>Fshr</i><sup>−/−</sup> mice, but not in male mice. Likewise, female, but not male <i>3xTg</i>;<i>Fshr</i><sup>−/−</sup> mice showed reduced fat mass at both the early and later time points, but without changes in total body mass. In contrast, in the <i>APP</i>-KI cohort, both female and male <i>Fshr</i><sup>-/-</sup> mice showed reduced fat mass at the early, but not the late time point. DXA revealed that female, but not male <i>APP-</i>KI;<i>Fshr</i><sup>−/−</sup> mice showed progressive increases with time in BMDs in tibiae, femora, and vertebrae, which were either statistically significant or approached significance. This phenotype was not observed on the <i>3xTg</i> background. These studies constitute the first report for time– and strain–dependent effects of global <i>Fshr</i> depletion in the same mouse, setting the stage for the simultaneous prevention, using a single therapeutic, of three disorders of public health magnitude—Alzheimer’s disease, obesity and osteoporosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fshr gene depletion prevents recognition memory loss, fat accrual and bone loss in Alzheimer’s mice

  • 期刊论文

  • 发表日期：

    2025年12月16日

查看全文
  • Uliana Cheliadinova,
  • Steven Sims,
  • Funda Korkmaz,
  • Darya Vasilyeva,
  • Victoria Laurencin,
  • Judit Gimenez-Roig,
  • Georgii Pevnev,
  • Guzel Burganova,
  • Zehra Tumoglu,
  • Surabhi Parte,
  • Farhath Sultana,
  • Anusha R. Pallapati,
  • Satish Rojekar,
  • Anne Macdonald,
  • Susan Hutchison,
  • Avi Soussan,
  • Anchine Liu,
  • Yi Wei,
  • Ofer Moldavski,
  • Anisa Gumerova,
  • Weibin Zhou,
  • Orly Barak,
  • Ki A. Goosens,
  • Vitaly Ryu,
  • Daria Lizneva,
  • Clifford J. Rosen,
  • Tony Yuen,
  • Tal Frolinger,
  • Mone Zaidi

摘要

Epidemiologic evidence links follicle–stimulating hormone (FSH), a pituitary glycoprotein that rises during menopause, to memory loss, fat accumulation, and bone loss. We and others have shown that the attenuation of FSH signaling, either genetically or pharmacologically, prevents memory loss, fat accrual, and bone loss in multiple mouse models. Here, we investigated whether the genetic depletion of the FSH receptor (Fshr) affects recognition memory, body composition, and bone mineral density (BMD) in two AD mouse models. We generated male and female 3xTg and APP-KI mice carrying the Fshr+/+, Fshr+/−, and Fshr−/− genotypes. Recognition memory was evaluated using the Novel Object Recognition (NOR) test. Body composition (fat, lean, and total mass) and site–specific bone mineral density (femur, tibia, L3–L5 spine) measurements were made using quantitative nuclear magnetic resonance (qNMR) and dual-energy X-ray absorptiometry (DXA), respectively, at two time points. Given that female Fshr−/− genotypes are otherwise hypogonadal, they were implanted with 17β–estradiol pellets at 8–12 weeks of age to normalize serum estrogen. At the early time point, the deficit in recognition memory was rescued in female 3xTg;Fshr−/− and APP-KI;Fshr−/− mice, but not in male mice. Likewise, female, but not male 3xTg;Fshr−/− mice showed reduced fat mass at both the early and later time points, but without changes in total body mass. In contrast, in the APP-KI cohort, both female and male Fshr-/- mice showed reduced fat mass at the early, but not the late time point. DXA revealed that female, but not male APP-KI;Fshr−/− mice showed progressive increases with time in BMDs in tibiae, femora, and vertebrae, which were either statistically significant or approached significance. This phenotype was not observed on the 3xTg background. These studies constitute the first report for time– and strain–dependent effects of global Fshr depletion in the same mouse, setting the stage for the simultaneous prevention, using a single therapeutic, of three disorders of public health magnitude—Alzheimer’s disease, obesity and osteoporosis.